Obstetrics, Gynecology and Reproduction

Advanced search
Online First
The pandemic of a new coronavirus infection COVID-19 has become a real challenge to humanity and the medical community and has raised a number of medical and social issues. From the currently available information on clinical cases of COVID-19, it follows that COVID-19 patients in critical condition have a clinical picture of disseminated intravascular coagulation (DIC), septic shock with the development of multiple organ failure, which justifies the anticoagulant therapy use in patients with COVID-19. In addition to isolating virus DNA from biological material and diagnosing SARS-CoV-2, the use of simple and easily accessible laboratory markers in the blood is necessary for the management of patients with COVID. If the activation of coagulation processes is sufficient enough, the consumption of platelets and blood clotting factors can be diagnosed by laboratory methods in the form of prolongation of routine blood clotting tests and increasing thrombocytopenia. Hyperfibrinogenemia, increased D-dimer, prolonged prothrombin time, thrombocytopenia, lymphopenia, leukocytopenia, increased interleukin 6, and ferritin are observed in most COVID-19 patients. The degree of increase in these changes correlates with the severity of the inflammatory process and is a prognostically unfavorable sign. In the article authors discuss laboratory monitoring that plays an essential role in this crisis, contributing to patient screening, diagnosis, as well as monitoring, treatment and rehabilitation.
COVID-19 is an infectious disease caused by the beta coronavirus SARS-CoV-2, which became widespread worldwide in 2020. In most severe patients, the clinical picture begins with respiratory failure, then progressing to polyorgan failure. The most adverse prognostic sign is the development of coagulopathy. Based on the analysis of clinical data available to date, 71.4% of those who died and 0.6% of those who survived showed signs of explicit disseminated intravascular coagulation syndrome (DIC-syndrome). Monitoring of D-dimer, prothrombin time (PT), platelet and fibrinogen count are important for determining treatment and indications for hospitalization among patients with COVID-19. If these parameters deteriorate, more "aggressive" intensive care should be performed. Lowmolecular weight heparin (LMWH) should be administered to all patients with diagnosed COVID-19 infection (including non-critical patients) who require hospitalization if these patients have no contraindications for LMWH.

ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)